[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"health-adult-subjects\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:health-adult-subjects":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,21,0,[8,46,73,102,129,159,179,204,228,253,273,294,318,339,365,387,408,445,470,503,526],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100644718","phase-1-an-early-stage-clinical-trial-to-evaluate-the-safety-absorption-and-disposition-of-yr001-ointment-following-topical-application-on-the-skin-of-healthy-chinese-subjects-100644718",false,"NCT07673458","An Early-stage Clinical Trial to Evaluate the Safety, Absorption, and Disposition of YR001 Ointment Following Topical Application on the Skin of Healthy Chinese Subjects","A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of YR001 Topical Ointment in Healthy Chinese Participants: A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study.","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form to participate in the study.\n\nMale or female, aged 18 to 65 years (inclusive).\n\nBody weight ≥ 50 kg and body mass index (BMI) between 18 and 30 kg\u002Fm² (inclusive).\n\nSkin at the intended application area is intact without ulceration, injury, sunburn, redness, rash, or other abnormalities at screening and prior to dosing.\n\nFemale participants of childbearing potential and all male participants must agree to use effective contraceptive methods during the study and for 3 months after the last dose.\n\nNo clinically relevant diseases, including dermatological conditions, as determined by medical history, physical examination, safety laboratory tests, and other assessments, that could adversely affect participant safety or study integrity or interfere with study results.\n\nWilling and able to comply with scheduled study visits, treatment administration, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* Current or history of clinically significant medical conditions or other disorders that may interfere with the assessment of safety, tolerability, or PK of YR001 Ointment, or place the participant at increased risk.\n\nPregnant or breastfeeding women, or participants with a positive pregnancy test.\n\nTattoos, scars, cuts, bruises, or other skin injuries (including excessive UV exposure) at the intended application site that, in the investigator's judgment, may affect drug absorption, distribution, metabolism, excretion, or trial safety.\n\nDermatological diseases or infections (e.g., acne, impetigo) or skin conditions at the intended application area that may interfere with study assessments, or that the investigator considers may affect drug absorption or skin observation.\n\nUnwilling to refrain from using depilatory creams or wax on the intended application area for 2 weeks prior to dosing and throughout the study.\n\nPositive test results at screening for hepatitis B surface antigen (HBsAg), hepatitis C virus IgG antibody (Anti-HCV), Treponema pallidum antibody (Anti-TP), or human immunodeficiency virus antibody (Anti-HIV).\n\nExisting renal impairment as judged by the investigator.\n\nExisting hepatic impairment as judged by the investigator.\n\nParticipation in another interventional clinical trial (e.g., investigational drug, biologic, or device) within 90 days prior to baseline, or currently in the follow-up period of another study, or prior participation in this clinical trial.\n\nUse of any over-the-counter (OTC) or prescription medications (including probiotics\u002Fprebiotics, vitamins, herbal supplements, and nutraceuticals, with the exception of acetaminophen\u002Fparacetamol) within 14 days prior to baseline, or receipt of vaccination within this period.\n\nCurrently diagnosed with acute or chronic inflammatory diseases (limited to autoimmune diseases and infectious diseases, e.g., tuberculosis). Participants whose disease symptoms have resolved for ≥ 12 months without any treatment may be considered in remission and eligible for enrollment.\n\nUse of topical skin products (including emollients) at the intended application site within 48 hours prior to baseline; use of topical products on non-application sites is permitted.\n\nClinically significant cardiac conduction abnormalities on electrocardiogram (ECG) as judged by the study physician.\n\nKnown allergy to the active substance or any excipient of the ointment.\n\nAny major surgery within 6 months prior to the screening period.\n\nDiagnosis of malignancy within 5 years prior to screening, with the exception of successfully treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n\nEmployees of the sponsor, clinical service organization, or clinical research site.\n\nHistory of drug abuse or substance use disorder within the past year; history of alcoholism within the past 6 months (as judged by the investigator); smoking \\> 5 cigarettes per day within the past 3 months, or inability to refrain from smoking during the study.\n\nAny other condition that, in the investigator's opinion, makes the participant unsuitable for participation in the clinical trial.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},18,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The goal of this clinical trial is to evaluate the safety, local tolerability, and pharmacokinetic (PK) profile of YR001 Topical Ointment in healthy Chinese participants. This is a first-in-China, Phase I study designed to assess the drug's systemic absorption and disposition following single and multiple topical applications.\n\nThe main questions it aims to answer are:\n\nWhat is the safety and local tolerability profile of YR001 Topical Ointment after single-dose and multiple-dose administration in healthy Chinese participants?\n\nWhat are the pharmacokinetic characteristics (e.g., plasma drug concentrations) of YR001 Topical Ointment after single and multiple topical applications?\n\nResearchers will compare participants receiving YR001 Topical Ointment with participants receiving vehicle (placebo) to determine whether the safety profile and local tolerability of YR001 are comparable to placebo.\n\nParticipants will:\n\nReceive topical application of either YR001 Topical Ointment or matching placebo (vehicle) on approximately 10% or 20% of their body surface area, depending on the assigned group\n\nUndergo serial blood sampling for pharmacokinetic assessments at specified time points before and after drug administration\n\nComplete safety evaluations including physical examinations, vital signs, laboratory tests (hematology, biochemistry, coagulation, thyroid function, urinalysis), 12-lead ECGs, and local tolerability assessments at the application site\n\nRemain in the clinical unit for specified periods during the dosing and follow-up phases, with total study participation duration up to approximately 30 days per participant",[28],"Health Adult Subjects",[30,31,32],"Phase 1","Double-Blind","Safety and Tolerability","RECRUITING","2026-06-29",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":37},"2026-06-22",{"date":41,"type":22},"2026-11-11",{"name":43,"class":44},"Hangzhou Yirui Pharmaceutical Technology Co., Ltd","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100644845","phase-1-a-study-to-evaluate-safety-tolerability-and-pharmacokinetics-of-orally-administered-tix100-in-healthy-subjects-100644845","NCT07675590","A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects","A Single Center, Multiple Dose, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects","Inclusion Criteria:\n\n1. Subjects aged 18-70 years, both genders.\n2. Healthy as determined by the Investigator, based on history, medical examination, vital signs, laboratory tests, cardiac monitoring and respiratory function. History must comply with the following:\n\n   1. Absence of clinically significant illness or surgery within the preceding 12 weeks.\n   2. Absence of clinically significant history of neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic, psychiatric, gastrointestinal, renal, hepatic, and\u002For metabolic disease.\n3. Male subjects with female partners of childbearing potential must agree to utilize condoms for the duration of the study.\n4. Female subjects of child-bearing potential with negative urine pregnancy tests and who agree to use double-barrier contraception during the study. The primary contraception may be oral contraceptives, hormonal implant or hormonal or non-hormonal intrauterine device, and the secondary (barrier) method of contraception with condom and\u002For with spermicide.\n5. Female subjects of non-child-bearing potential (i.e. bilateral tubal ligation (BTL), bilateral tubal occlusion (BTO), bilateral salpingectomy, hysterectomy, partial hysterectomy, bilateral oophorectomy, or postmenopausal, defined as no menses for 12 months without an alternative medical cause).\n6. Body mass index (BMI) 25 - 34.9 kg\u002Fm2\n7. HbA1c \\\u003C6.5%\n8. Willingness to fully comply with protocol.\n\nExclusion Criteria:\n\n1. History of excessive alcohol use (defined as \\>21 drinks per week for males and \\>14 drinks per week for females), recreational drug use or drugs of abuse within the past three months, or failure on urinary drug screen.\n2. Pregnant or breastfeeding within six months of screening assessment.\n3. Substantial changes in eating habits or exercise routines within the preceding three months.\n4. Evidence of eating disorders.\n5. \\>5% weight change in the past three months.\n6. Bariatric surgery within the past five years.\n7. Significant renal impairment (eGFR \\\u003C60 mL\u002Fmin\u002F1.73m2).\n8. Liver function tests (i.e., ALT, AST, alkaline phosphatase) greater than twice the upper limit of normal upon repeated measurements.\n9. Diseases interfering with metabolism and\u002For ingestive behavior (e.g., myxedema, Cushing's disease, schizophrenia, major psychoses, unmanaged depression).\n10. Use of prescription medications during screening and duration of the trial.\n11. Use of drugs approved for the treatment of obesity.\n12. Any clinically significant abnormality following the Investigator's review of the physical examination and clinical laboratory tests.\n13. A baseline prolongation of QT\u002FQTcF interval after repeated measurements of \\>450 ms for men and \\>470 for women; a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of LQTS.\n14. Participation in an investigational drug trial within three months prior to dosing in the present study.","70 Years",{"count":21,"type":22},[25],"Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight\u002Fobese subjects.",[28,58],"Obesity & Overweight",[60,61,62,63,64],"inhibitor of thioredoxin-interacting protein","TXNIP","TIX100","TIXiMED","Type 1 Diabetes","2026-06-25",{"date":67,"type":37},"2026-06-30",{"date":39,"type":22},{"date":70,"type":22},"2026-12",{"name":72,"class":44},"TIXiMED, Inc.",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":91,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":99,"locationsCount":45},"100606648","assessment-of-pressure-pain-threshold-ppt-and-conditioned-pain-modulation-cpm-after-effect-in-patients-with-and-without-tennis-elbow-te-100606648","NCT07178288","Assessment of Pressure Pain Threshold (PPT) and Conditioned Pain Modulation (CPM) After Effect in Patients With and Without Tennis Elbow (TE)","Measurement Properties and Temporal Stability of Conditioned Pain Modulation in Individuals With and Without Lateral Epicondylalgia","TE Group\n\nInclusion Criteria:\n\nPatients with Tennis Elbow confirmed at initial assessment by the Primary Investigator (PI)\n\nUnilateral elbow pain \\> 6 weeks duration reproduced on at least two of the following tests:\n\n* Palpation of the lateral epicondyle\n* Isometric testing of the wrist extensors\n* Middle finger extension test\n* Passive stretch of wrist extensors\n* Resisted hand gripping using a dynamometer\n* Upper limb neurodynamic test-radial nerve bias (ULNDT-RN)\n\nExclusion Criteria:\n\n* History of chronic pain conditions (e.g. fibromyalgia, irritable bowel\n* syndrome, temporomandibular dysfunction, migraines)\n* Neurological or sensory dysfunction (especially in the upper limbs)\n* History of chronic musculoskeletal pain (e.g. arthritis, chronic low back\n* pain)\n* Contraindications to cold application (i.e. Reynaud's disease, diabetes)\n* Current or long-term use of pain medication or anti-depressants\n\nHealthy Group The asymptomatic group included adults (18-65 years) without pain (acute or chronic) at least 3 months before the experimental sessions.","60 Years",{"count":82,"type":22},38,[84],"NA","This study at Hashemite University looks at how people with and without tennis elbow (AKA lateral elbow tendinopathy) feel pressure pain and how their bodies briefly \"turn down\" pain after a cold stimulus. Participants complete brief questionnaires (basic demographics without names, a tennis-elbow symptom form, and a physical-activity form) and then have their pressure-pain threshold (PPT) tested with a handheld device that slowly increases pressure on standard spots near the elbow and wrist; they say when it first becomes painful. To test the body's built-in anti-pain system (conditioned pain modulation, CPM), one hand is placed in ice water (the cold-pressor task) and PPT is measured again at set times (before, during, and after the cold stimulus) to see how much pain sensitivity changes and how long that change lasts. Both PPT reliability and CPM after effect are measured in this study. The study findings may help improve future assessment and treatment of musculoskeletal pain conditions.",[87,28,88,89,90],"Tennis Elbow","Lateral Elbow Tendinopathy (Tennis Elbow)","Pressure Pain Threshold (PPT)","Conditioned Pain Modulation (CPM)",[92],"Lateral elbow tendinopathy (tennis elbow), pressure pain threshold (PPT), conditioned pain modulation (CPM)","2026-06-23",{"date":95,"type":37},"2026-06-26",{"date":97,"type":37},"2025-09-10",{"date":67,"type":22},{"name":100,"class":101},"The Hashemite University","OTHER",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":45},"100600734","acute-effects-of-aerobic-exercise-and-high-intensity-interval-exercise-with-immersive-virtual-reality-100600734","NCT07101341","Acute Effects of Aerobic Exercise and High-intensity Interval Exercise With Immersive Virtual Reality","Analysis of the Acute Effects of Aerobic Exercise and High-intensity Interval Exercise, With and Without the Simultaneous Application of Immersive Virtual Reality","Inclusion Criteria:\n\n* Healthy people between 18 and 35 years old\n\nExclusion Criteria:\n\n* Current or recent injury that affects training\n* Condition that prevents exercise (decompensated heart disease, decompensated respiratory disease, significant mobility difficulties, etc.)\n* Visual problems that prevent exercise with virtual reality headsets","35 Years",{"count":111,"type":22},45,[84],"This study aims to compare the acute effects at the cardiovascular (heart rate, blood pressure) and physiological (lactate) levels, as well as the perception of effort and fatigue, of four exercise modalities, one based on the traditional aerobic training methodology, another based on high-intensity interval training (HIIT), another consisting of aerobic exercise performed in conjunction with an immersive virtual reality (VR) application, and a last one consisting of exercise with HIIT-type parameters but also performed in conjunction with an immersive VR application.\n\nAll participants will complete one session of each of the four exercise modalities, analyzing the variables studied in each for subsequent analysis and comparison.",[115,28],"Acute Effects of Exercise in Healthy People",[117,118,119],"virtual reality","immersive virtual reality","exergame","2026-06-08",{"date":122,"type":37},"2026-06-10",{"date":124,"type":37},"2026-02-25",{"date":126,"type":22},"2027-06",{"name":128,"class":101},"University of Valencia",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":45},"100636988","alter-ego-as-an-assistive-robotic-device-100636988","NCT07572838","Alter-Ego as an Assistive Robotic Device.","Alter-Ego as an Assistive Robotic Device for Hospital and Domestic Applications.","Alter-Ego","* Inclusion Criteria\n\n  * Healthcare Professionals\n\n    1. Age within the legal working age range for professional employment.\n    2. Experience in the management and treatment of patients affected by motor neuron disease.\n    3. Expected employment at ICS Maugeri IRCCS, Milan Camaldoli, for the entire duration of the study.\n    4. Ability to understand and provide informed consent.\n  * Patients\n\n    1. Diagnosis of possible, probable, or definite Amyotrophic Lateral Sclerosis (ALS) according to the El Escorial criteria.\n    2. Adults aged between 18 and 80 years.\n    3. Ability to understand and provide informed consent.\n    4. Absence of psychiatric disorders or psychological conditions that, in the physician's judgment, could cause stress during interaction with the robot.\n\n       \\---\n* Exclusion Criteria\n\n  * Healthcare Professionals\n\n    1\\. Health conditions that, in the clinician's judgment, could make the use of the Alter-Ego system via a head-mounted display unsafe or inappropriate.\n  * Patients\n\n    1. Individuals with severe psychiatric disorders or cognitive impairments that compromise the ability to complete assessment scales (based on medical history data).\n    2. Individuals with moderate to severe cognitive impairment, defined as a score below 81.92 on the ECAS questionnaire (routinely administered during the first days of hospitalization).\n    3. Individuals in isolation due to infectious causes.","80 Years",{"count":139,"type":22},52,"OBSERVATIONAL","The ALTER-EGO study is a monocentric, observational clinical investigation designed to evaluate the safety, usability, and feasibility of the humanoid robotic platform Alter-Ego as an assistive device in hospital and simulated home-care settings. The system is intended to support healthcare and rehabilitation professionals in the management of patients with Amyotrophic Lateral Sclerosis (ALS). Alter-Ego is an anthropomorphic, wheeled, self-balancing social robot equipped with compliant robotic arms and SoftHand synergistic grippers. It operates in teleoperated, semi-autonomous, or fully autonomous modes and integrates advanced navigation, mapping, object manipulation, and natural language processing capabilities. The robot is not classified as a medical device under EU Regulation 2017\u002F745, as it does not perform diagnostic or therapeutic functions, but provides logistical, communicative, and organizational support.\n\nThe study is conducted at ICS Maugeri IRCCS (Milan Camaldoli). Participants include healthcare professionals (physicians, nurses, physiotherapists, occupational therapists, speech therapists, and healthcare assistants) and up to 40 hospitalized ALS patients. Patients are not direct operators of the robot but provide experiential feedback.\n\nA total of 40 experiments are organized into four clusters:\n\nCluster 1 - Telemedicine (Teleoperated or Semi-Autonomous Mode)\n\nWithin a simulated home-care environment, Alter-Ego supports remote clinical and rehabilitation activities through four specific tasks:\n\nSimulated Remote Medical Visit (First Home Transition):\n\nA physician conducts a tele-visit via the robot, asking health-related questions, performing visual neurological assessments using cameras and microphones, requesting specific motor tasks, and reviewing vital parameters from home monitoring devices. This task addresses the need for expert supervision during early discharge phases.\n\nAssistive Device Training:\n\nA physiotherapist and nurse remotely verify and guide the correct use of assistive devices such as non-invasive ventilation systems, PEG, or patient lifters, providing practical instructions to patients and caregivers.\n\nHome Environment Assessment:\n\nAn occupational therapist uses the robot in semi-autonomous mode to map the domestic environment and, in tele-guided mode, visually inspect spaces to identify architectural barriers and optimize assistive device placement.\n\nTelerehabilitation:\n\nPhysiotherapists and speech therapists use the robot's audio-video interface and display to conduct remote rehabilitation sessions and functional evaluations, providing visual and verbal feedback.\n\nCluster 2 - Delivery Services (Autonomous Mode) The robot autonomously transports small items within the hospital ward, including medical records, blood collection kits, rehabilitation tools, and small food or beverage packages.\n\nCluster 3 - Guidance and Welcome Assistance (Autonomous Mode) Alter-Ego presents ward service information to newly admitted patients and provides personalized daily reminders regarding scheduled rehabilitation activities.\n\nCluster 4 - Monitoring (Autonomous Mode) The robot administers the Visual Analog Scale (VAS) for pain assessment and includes an exploratory function for detecting vocal distress keywords (e.g., \"pain,\" \"help,\" \"thirst\") using AI-based speech recognition, alerting staff when necessary.\n\nPrimary endpoints include usability and feasibility (System Usability Scale - SUS; Questionnaire for User Interaction Satisfaction - QUIS; NASA Raw Task Load Index - NASA-RTLX) and safety assessment through systematic recording of adverse events.\n\nSecondary outcomes include healthcare professionals' satisfaction with autonomous robot performance, patient satisfaction (Likert scales), and psychosocial impact on professionals (selected PIADS items).\n\nThe ALTER-EGO study aims to determine whether an anthropomorphic robotic platform can safely and effectively support multidisciplinary ALS care, improve workflow efficiency, and enhance patient-centered assistance in both hospital and transitional home-care settings.",[143,28],"Amyotrophic Lateral Sclerosis",[145,146,147,148],"Humanoid robotic platform","Assistive Device","Telemedicine","Healthcare","NOT_YET_RECRUITING","2026-04-30",{"date":152,"type":37},"2026-05-07",{"date":154,"type":22},"2026-05",{"date":156,"type":22},"2026-11",{"name":158,"class":101},"University of Pisa",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":45},"100636041","impact-of-a-wheat-based-fermented-beverage-on-microbiota-and-metabolic-health-in-healthy-individuals-100636041","NCT07560527","Impact of a Wheat-based Fermented Beverage on Microbiota and Metabolic Health in Healthy Individuals","Inclusion Criteria:\n\n* Body Mass Index (BMI) between 18.5 and 24.9 kg\u002Fm²\n* Healthy status\n* Willingness to consume a fermented wheat-based beverage daily for 4 weeks\n* Capacity and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Use of antibiotics and\u002For probiotics in the 12 weeks prior to the study\n* Weight variation \\>10% within the last 3 months\n* Participation in any clinical study or trial within the previous 12 months\n* Diagnosed medical conditions, including: diabetes, liver disease (e.g., cirrhosis), pancreatitis or other malabsorption syndromes, gastrointestinal disorders (e.g., inflammatory bowel disease, celiac disease), history of weight-loss surgery (e.g., bariatric surgery), chronic respiratory, neurological, psychiatric, musculoskeletal, or other systemic conditions, eating disorders\n* Diagnosed food allergies or intolerances\n* Pregnancy or breastfeeding",{"count":166,"type":22},20,[84],"The proposed study aims to evaluate the impact on intestinal and oral microbiota composition and the metabolic effects of the daily consumption of a wheat-based fermented beverage, developed under the collaborative WHEATBIOME project, over a 4-week intervention period in healthy adults.",[28],"2026-04-27",{"date":172,"type":37},"2026-05-01",{"date":174,"type":22},"2026-05-20",{"date":176,"type":22},"2026-12-31",{"name":178,"class":101},"Universidade Nova de Lisboa",{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":187,"studyType":140,"phases":4,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":45},"100635402","muscle-imaging-project-using-anatomopathology-and-full-field-optical-coherence-tomography-100635402","NCT07552220","Muscle Imaging Project Using ANatomopathology and Full Field Optical Coherence Tomography","PIMANT","Inclusion Criteria:\n\n* Patient \\> 18 years old ans has given his oral consent\n* Patient who biospies are performed as part of care\n\nExclusion Criteria:\n\n* Patient \\\u003C 18 years old",{"count":166,"type":22},"1 Day","Myositis is an inflammatory disease of the skeletal muscles that can be caused by infections, autoimmune diseases, or medications. Early diagnosis of these conditions is essential for optimal treatment. Anatomic pathology is the conventional method used to analyze muscle lesions, but it requires several weeks to obtain results. Full-field optical coherence tomography (OCT), a non-invasive imaging technique, could offer advantages in terms of speed and resolution for visualizing muscle inflammation.\n\nThis research project compares histological pathology and full-field OCT for the analysis of muscle biopsies from healthy individuals and patients suspected of having myositis. The aim of this study is to establish an OCT reference standard by analyzing control muscle biopsies and then comparing muscle inflammation in confirmed cases of myositis. The advantages and limitations of both methods will also be evaluated.",[190,28],"Myositis",[192,193,194,195],"anatomopathology","Full field optical coherence tomography","muscle biopsies","Myositis and healthy patients","2026-04-20",{"date":170,"type":37},{"date":199,"type":22},"2026-04",{"date":201,"type":22},"2028-12",{"name":203,"class":101},"Centre Hospitalier de Mâcon",{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":211,"enrollmentInfo":212,"targetDuration":4,"studyType":23,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":45},"100634051","phase-1-a-study-of-jph034-in-healthy-adult-participants-100634051","NCT07534657","A Study of JPH034 in Healthy Adult Participants","A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-ascending Doses of JPH034 in Healthy Adult Male and Female Participants","Inclusion Criteria:\n\n1. Age 18 to 50 years, inclusive, at the time of Screening.\n2. Body mass index (BMI) ≥ 18.5 and ≤ 34 kg\u002Fm2 at Screening and Check-in. Sex and Contraceptive\u002FBarrier Requirements\n3. Females who are not pregnant or breastfeeding, agree to refrain from donating eggs during the study intervention period and for at least 30 days after the last dose of study intervention, and who meet one of the following conditions:\n\n   1. Postmenopausal (no menses for 12 months, without an alternative medical cause; Section 10.2.1), or\n   2. Permanent infertility (documented hysterectomy, bilateral salpingectomy, or bilateral oophorectomy), or\n   3. Agree to abstain from heterosexual intercourse or to use a highly effective method of contraception (listed in Section 10.2.2) during the study intervention period and for at least 30 days after the last dose of study intervention.\n4. Females with a negative serum pregnancy test at Screening and a negative urine pregnancy test at Check-in (within 24 hours before the first dose of study intervention).\n5. Males who agree to the following conditions during the study intervention period and for at least 30 days after the last dose of study intervention:\n\n   1. Refrain from donating sperm and\n   2. Use one of the following forms of contraception:\n\n      * Abstinence from heterosexual intercourse or\n      * Condom if partner is a woman of CBP (defined in Section 10.2.1), plus highly effective method of contraception (listed in Section 10.2.2) if partner is a woman of CBP who is not currently pregnant.\n6. Willing and able to provide voluntary, written informed consent to participate in the study.\n7. Able to communicate well with the Investigator and\u002For study site personnel and to comply with the requirements of the entire study.\n8. Negative drug\u002Falcohol testing at Screening and Check-in.\n9. Vital signs (after semi-recumbent for at least 5 minutes) that are within the following ranges at Screening and Check-in. If not within the stated ranges, they must be without clinical significance as determined by the Investigator.\n\n   1. Systolic BP, 90 to 140 mmHg, inclusive\n   2. Diastolic BP, 50 to 90 mmHg, inclusive\n   3. Heart rate (HR), \\> 45 to ≤ 100 bpm\n10. Normal renal function, defined as eGFR \\> 90 mL\u002Fmin at Screening; an Investigator can determine based on clinical judgment whether a lower rate can be accepted based on the muscle composition of the participants.\n\nExclusion Criteria:\n\n1. History or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrinological, hematological, neurological, or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.\n2. History of any active infection within 14 days of dosing with study intervention, if deemed clinically significant by the Investigator and Sponsor.\n3. Any acute illness within 30 days prior to dosing with study intervention.\n4. Clinically significant (as determined by the Investigator) abnormal laboratory test results, including, but not limited to, lipase, amylase, alkaline phosphatase, WBC count, or platelets, at Screening and Check-in. Note: Alkaline phosphatase, WBC count, and platelets must be within normal limits at Screening and Check-in.\n5. Concurrent conditions that could interfere with safety and\u002For tolerability measurements, as determined by the Investigator or designee.\n6. Existence of any surgical or medical condition that, in the judgment of the Investigator, might interfere with the absorption, distribution, metabolism, or excretion of JPH034.\n7. History (within 2 years prior to the first dose of study intervention) of moderate or severe use disorder for any substance other than caffeine (based on DSM-5 criteria).\n8. History of a major psychiatric disorder, ongoing suicidal ideations, or endorsement of suicidal ideation or behavior based on the C-SSRS at Screening.\n9. Reduced sense of taste, as assessed by taste strips at Screening.\n10. QTcF \\> 450 msec for males or \\> 470 msec for females observed at Screening or Check-in.\n11. History or presence of any type of arrhythmia or irregular heartbeat.\n12. Long QT syndrome or a history of cardiac disease.\n13. Potassium or magnesium outside the normal range at Screening or Check-in (potassium normal range = 3.6-5.2 mEq\u002FL; magnesium normal range = 1.9-2.7 mg\u002FdL).\n14. Use of any drug known to prolong the QT interval within 4 weeks prior to study.\n15. ALT or AST \\> 1.5 × ULN at Screening or Check-in.\n16. Total bilirubin \\> 1.5 × ULN at Screening or Check-in. For participants with known Gilbert's syndrome these criteria only apply if total bilirubin \\> 1.5 × ULN as long as direct bilirubin is ≤ 1.5 × ULN.\n17. Current or chronic history of liver disease. This includes but is not limited to hepatitis virus infections, drug- or alcohol-related liver disease, steatotic liver disease, autoimmune hepatitis, hemochromatosis, Wilson's disease, α-1 antitrypsin deficiency, primary biliary cholangitis, primary sclerosing cholangitis, or any other liver disease considered clinically significant by the Investigator.\n18. Use of prescription or non-prescription medications within 14 days or 5 half-lives, whichever is longer, before the first dose of study intervention.\n19. Exposure to any investigational agent within 5 half-lives or 30 days, whichever is longer, prior to Screening.\n20. Diagnosis of or positive Screening result for HCVAb, or HIV-1 or HIV-2.\n21. Diagnosis of or positive Screening result for current or previous natural hepatitis B infection. Results indicative of vaccine-induced immunity (negative HBsAg and HBcAb plus positive HBsAb) will not be exclusionary.\n22. Positive COVID-19 test.\n23. Positive or indeterminate IGRA (QuantiFERON®-TB Gold Plus \\[QFT-Plus\\]) TB test.\n24. Known history of allergy to JPH034 or other related drugs or their components.\n25. Any food allergy, intolerance, restriction, or special diet that, in the opinion of the Investigator or designee, could contraindicate the participant's participation in the study.\n26. Unable to ingest an entire high-fat\u002Fhigh-calorie meal.\n27. Blood donation (excluding plasma donation) of approximately 500 mL within 56 days prior to Screening.\n28. Plasma donation within 7 days of Screening.\n29. Unable or unwilling to cooperate with site staff for any reason.\n30. Study site employees, immediate family members of a study site employee, or anyone whose participation in the study would create a conflict of interest for a study site employee.","50 Years",{"count":213,"type":22},40,[25],"This study is designed to evaluate the safety, tolerability, and PK of JPH034 and identify side effects that occur in healthy participants between the ages of 18 and 50 years. Participants enrolling in the trial will be randomly assigned to receive JPH034 or placebo. Participants in the in single-ascending dose (SAD) cohorts will receive treatment once, and one group of participants will receive treatment a second time to study the effects of food. Health measurements including physical examinations, vital signs, ECGs, and safety laboratory tests will be performed to monitor safety. Blood tests will be performed to measure how much JPH034 and its major metabolite (M1) gets into the bloodstream and how long it stays in the body.",[28],[218],"Single Ascending Dose","2026-04-14",{"date":221,"type":37},"2026-04-16",{"date":223,"type":22},"2026-03-22",{"date":225,"type":22},"2026-10-10",{"name":227,"class":44},"J-Pharma Co., Ltd.",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":236,"targetDuration":4,"studyType":23,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":250,"leadSponsor":251,"locationsCount":4},"100634406","device-for-driving-simulation-for-the-rehabilitation-of-balance-and-proprioception-100634406","NCT07539272","Device for Driving Simulation for the Rehabilitation of Balance and Proprioception","A Multicenter Interventional Study on the Use of a Driving Simulator to Assess the Safety and Usability of the System and Its Impact on Motor and Cognitive Performance in the Rehabilitation of Patients With Neurological Disorders","DRIVESIM","Inclusion Criteria:\n\n* Patients: adults aged 18 to 80 years.\n* Patients: confirmed diagnosis of one of the following chronic neurological conditions: stroke, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or mild cognitive impairment (MCI).\n* Patients: able to understand and follow study procedures and provide informed consent.\n* Healthy volunteers: adults aged 18 to 65 years.\n* Healthy volunteers: able to understand and follow study procedures and provide informed consent.\n* Healthy volunteers: rehabilitation staff members from the participating centers.\n\nExclusion Criteria:\n\n* Patients: severe psychiatric disorders or cognitive disorders that impair the ability to complete cognitive tests and self-report questionnaires.\n* Patients: unable to provide informed consent.\n* Patients: moderate to severe cognitive impairment, defined as an ECAS score below 81.92 in participants with ALS or a Raven's Matrices score below 18.36 in participants with mild cognitive impairment.\n* Patients: neurological or physical conditions that significantly limit lower-limb use and prevent standing on the platform, including lower-limb muscle strength of 3 or less on the Medical Research Council (MRC) scale.\n* Patients: body weight greater than 100 kg.\n* Patients: current or recent participation, within the last 3 months, in other rehabilitation programs or interventions that could affect study results.\n* Patients: alcohol or substance dependence that could compromise safety during training sessions.\n* Patients: unstable health conditions that could make use of the DRIVESIM and\u002For head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions.\n* Healthy volunteers: health conditions that could make use of the DRIVESIM and\u002For head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions.\n* Healthy volunteers: any motor disability.",{"count":237,"type":22},60,[84],"The DriveSim clinical trial investigates a dynamic driving simulator designed to train and assess functional motor and cognitive skills in individuals with neurological disorders. The study addresses a critical need in current rehabilitation practice, where maintaining patient engagement and providing ecologically valid training environments are essential yet challenging. Neurological conditions such as stroke, Parkinson's disease, amyotrophic lateral sclerosis and mild cognitive impairment often result in deficits in balance, proprioception, coordination, attention and motor planning, all of which critically affect daily functioning and driving ability. The novelty of this study lies in the integration of a three-degree-of-freedom motion platform with active steering, customizable haptic and inertial feedback, and adaptive task modules in a virtual urban scenario. This enables controlled, multisensory rehabilitation sessions that combine motor, vestibular and cognitive stimuli in a single system. The primary objective of the trial is to evaluate the safety, usability and feasibility of the DriveSim platform in both healthy individuals and patients with neurological impairment. Secondary objectives include assessing its impact on postural control, trunk and head stability, upper and lower limb motor performance, cognitive functions, perceived stress and fatigue, and quality of life. The study also aims to support the development of adaptive software capable of automatically adjusting task difficulty based on patient performance. By integrating functional tasks such as slalom, speed control, line keeping and reaction tests with customizable sensory feedback, this research has the potential to enhance the ecological validity of rehabilitation and to provide individualized motor-cognitive training. The expected outcome is a more engaging, adaptable and measurable rehabilitation pathway that may improve functional independence and support safer driving-related abilities in neurological populations.",[241,28],"Neurological Disorders",[243,244,245,246],"neurological rehabilitation","driving simulator","dynamic platform","motor-cognitive training","2026-04-13",{"date":196,"type":37},{"date":199,"type":22},{"date":156,"type":22},{"name":252,"class":101},"University of Pavia",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":261,"briefSummary":262,"conditions":263,"keywords":264,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":271,"leadSponsor":272,"locationsCount":4},"100631611","a-multicenter-interventional-study-on-the-use-of-a-3-degree-of-freedom-3dof-platform-to-evaluate-the-safety-and-usability-of-the-system-and-its-impact-on-balance-proprioception-and-neurological-deficits-in-the-rehabilitation-of-patients-with-neurological-disorders-100631611","NCT07502937","A Multicenter Interventional Study on the Use of a 3-Degree-of-Freedom (3DOF) Platform to Evaluate the Safety and Usability of the System and Its Impact on Balance, Proprioception, and Neurological Deficits in the Rehabilitation of Patients With Neurological Disorders.","3DOF","Inclusion Criteria:\n\n* Patients: adults aged 18 to 80 years.\n* Patients: confirmed diagnosis of one of the following chronic neurological conditions: stroke, Parkinson's disease, amyotrophic lateral sclerosis (ALS), or mild cognitive impairment (MCI).\n* Patients: able to understand and follow study procedures and provide informed consent.\n* Healthy volunteers: adults aged 18 to 65 years.\n* Healthy volunteers: able to understand and follow study procedures and provide informed consent.\n* Healthy volunteers: rehabilitation staff members from the participating centers.\n\nExclusion Criteria:\n\n* Patients: severe psychiatric disorders or cognitive disorders that impair the ability to complete cognitive tests and self-report questionnaires.\n* Patients: unable to provide informed consent.\n* Patients: moderate to severe cognitive impairment, defined as an ECAS score below 81.92 in participants with ALS or a Raven's Matrices score below 18.36 in participants with mild cognitive impairment.\n* Patients: neurological or physical conditions that significantly limit lower-limb use and prevent standing on the platform, including lower-limb muscle strength of 3 or less on the Medical Research Council (MRC) scale.\n* Patients: body weight greater than 100 kg.\n* Patients: current or recent participation, within the last 3 months, in other rehabilitation programs or interventions that could affect study results.\n* Patients: alcohol or substance dependence that could compromise safety during training sessions.\n* Patients: unstable health conditions that could make use of the 3DoF Platform and\u002For head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions.\n* Healthy volunteers: health conditions that could make use of the 3DoF Platform and\u002For head-mounted display unsafe or inappropriate, such as severe cardiovascular disease, severe respiratory disease, or other unstable medical conditions.\n* Healthy volunteers: any motor disability.",{"count":237,"type":22},[84],"This multicenter interventional study aims to evaluate a three-degrees-of-freedom dynamic platform (3DoF Platform) designed to support rehabilitation of balance, proprioception, and motor and cognitive functions in patients with neurological disorders. The device integrates a mobile platform capable of roll, pitch, and vertical translation movements, a markerless motion-capture system, and an interactive environment delivered through a monitor or virtual reality headset. Compared with conventional rehabilitation systems, it offers an additional vertical degree of freedom and increased proprioceptive stimulation, with the ability to customize exercises according to individual patient capabilities. The clinical conditions under investigation include Parkinson's disease, post-stroke motor impairment, amyotrophic lateral sclerosis, and mild cognitive impairment, all of which are associated with deficits in balance and proprioception. The novelty of this study lies in the combined use of the 3DoF platform, the markerless acquisition system, and exergames integrated with a mathematical model that adapts the platform's dynamic response in real time. The primary objective is to assess the usability, feasibility, and safety of the device. Secondary objectives include evaluating the impact of the intervention on balance, motor performance, cognitive functions, stress, fatigue, and quality of life, as well as comparing conventional rehabilitation with and without the addition of the device. The study involves 45 patients and 15 healthy volunteers and is structured into an initial phase of testing on healthy subjects and a subsequent randomized two-arm treatment phase for patients.",[241,28],[265,266,119,243],"3DoF Platform","proprioception","2026-03-31",{"date":269,"type":37},"2026-04-06",{"date":199,"type":22},{"date":156,"type":22},{"name":252,"class":101},{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":16,"sex":280,"minAge":18,"maxAge":281,"enrollmentInfo":282,"targetDuration":4,"studyType":23,"phases":284,"briefSummary":285,"conditions":286,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":291,"leadSponsor":292,"locationsCount":45},"100631073","phase-1-pharmacokinetic-characteristics-safety-and-immunogenicity-of-hlx319-compared-with-eu-phesgo-100631073","NCT07495930","Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With EU-Phesgo®","A Randomized, Double-blind, Single Subcutaneous Administration, Parallel Control Phase I Clinical Study to Compare the Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 and EU-Phesgo® in Chinese Healthy Male Subjects.","Inclusion Criteria:\n\n1. Male subjects aged ≥18 and ≤45 years;\n2. The skin at the injection site is intact, without damage, tattoos, or other markings;\n3. Subjects have no history of disease or past medical history abnormalities that, in the judgment of the study physician, would affect the trial;\n4. Physical examination, vital signs, chest x-ray, electrocardiogram, and laboratory investigations are normal or show abnormalities without clinical significance.\n5. Body weight (BW) ≥50 and ≤75 kg;\n6. Body mass index (BMI) ≥19 and ≤24 kg\u002Fm² \\[BMI = weight (kg) \u002F height² (m²)\\];\n7. Within 14 days prior to random allocation, left ventricular ejection fraction (LVEF) assessed by echocardiography is within the normal range (≥55%);\n\nExclusion Criteria:\n\n1. Clinically significant diseases including but not limited to the gastrointestinal tract, kidneys, liver, nerves, blood, endocrine system, tumors, respiratory system, immune system, mental health, and cardiovascular and cerebrovascular diseases;\n2. History of allergy or hypersensitivity reactions.\n3. Intake of prescription drugs, over-the-counter drugs, or traditional Chinese medicine within 28 days prior to randomization;\n4. History of blood donation or blood loss (\\>450mL) within 3 months prior to randomization;\n5. Positive test results for Hepatitis B Surface Antigen (HbsAg), Hepatitis C Virus (HCV) antibodies, and Human Immunodeficiency Virus (HIV) antibodies, or abnormal and clinically significant quantitative test results for syphilis spirochetes as determined by the sub investigator;\n6. History of upper respiratory tract infection or other acute infections within 2 weeks prior to r randomization;\n7. History of drug abuse, substance use;\n8. History of alcoholism or positive alcohol test results;\n\n11\\. History of long-term heavy smoking .","MALE","45 Years",{"count":283,"type":22},24,[25],"The study is being conducted to compare the pharmacokinetic (PK) parameters of HLX319 and EU-Phesgo® after a single subcutaneous administration in healthy male subjects in China, providing a basis for the design of subsequent clinical study protocols.",[28],"2026-03-26",{"date":289,"type":37},"2026-04-01",{"date":150,"type":22},{"date":225,"type":22},{"name":293,"class":44},"Shanghai Henlius Biotech",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":16,"sex":301,"minAge":18,"maxAge":281,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":307,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":45},"100613747","eight-week-sports-injury-prevention-program-100613747","NCT07270614","Eight-week Sports Injury Prevention Program","Effects of an 8-Week Injury Prevention Program on Lower Limb Performance in Female Athletes: Quasi-Experimental Evidence","Inclusion Criteria:\n\n* Female athletes aged 18-35 years\n* Actively participating in organized sports in Saudi Arabia\n* Minimum of one year of continuous experience in their sport\n* Currently engaged in regular training and\u002For competition\n* Able to perform physical activity safely as confirmed by self-report\n* Willing to provide informed consent and complete all study assessments\n\nExclusion Criteria:\n\n* Any recent injury within the past six months that limits performance\n* Pregnancy at the time of enrollment\n* Diagnosis of a chronic medical condition that may affect performance (e.g., uncontrolled diabetes, uncontrolled hypertension)\n* Any condition that could interfere with safe participation in physical testing or training\n* Refusal or inability to provide informed consent","FEMALE",{"count":303,"type":22},30,[84],"This study aims to find out whether an 8-week sports injury prevention program can improve lower-body performance-such as power, agility, and balance-among female college athletes in Saudi Arabia.\n\nSports participation has increased among women in Saudi Arabia, but many injury-prevention programs were originally designed for male athletes and may not meet the specific needs of females. This study will help determine whether a tailored program can reduce injury risks and improve athletic performance.\n\nFemale athletes aged 18-35 years who have been training and competing for at least one year can participate. Athletes with recent injuries, pregnancy, or chronic medical conditions that could affect performance will not be included.\n\nParticipants will complete tests before and after the program, including jumping, balance, and agility assessments. The prevention program includes warm-up exercises, stretching, strengthening, jumping drills, balance work, and agility training.\n\nBy comparing results before and after the program, the study will show whether this type of training can help female athletes stay safer and perform better.",[28],[308],"Injury prevention program","2026-03-20",{"date":311,"type":37},"2026-03-24",{"date":313,"type":37},"2025-08-16",{"date":315,"type":22},"2026-03-17",{"name":317,"class":101},"Princess Nourah Bint Abdulrahman University",{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":323,"acronym":4,"eligibilityCriteria":324,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":137,"enrollmentInfo":325,"targetDuration":4,"studyType":23,"phases":327,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":333,"completionDateStruct":335,"leadSponsor":337,"locationsCount":45},"100619439","effects-of-nr-supplementation-on-metabolic-flexibility-in-zone-2-training-100619439","NCT07344636","Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training","Temporal and Dose-response Effects of Nicotinamide Riboside Supplementation on Metabolic Flexibility During Zone 2 Training in Adults: a Double-blinded, Randomized, Controlled, Crossover Trial","Inclusion Criteria:\n\n* Over 18 years old\n* BMI \\\u003C30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Present of health conditions that contraindicate participation in exercise training, such as a history of cardiovascular disease, cancer, or musculoskeletal disorders\n* Currently taking vitamin B supplements and\u002For NAD precursors\n* Taking medication that may affect the test results",{"count":326,"type":22},16,[84],"Zone 2 training, a low-intensity endurance exercise performed at approximately 66-80% of VO₂max or near the first ventilatory threshold, has gained popularity for improving aerobic capacity, fat metabolism, and mitochondrial efficiency. It preserves glycogen stores and delays fatigue, making it an essential training method for both athletes and recreational exercisers. Nicotinamide adenine dinucleotide (NAD) is a vital metabolite that regulates cellular energy metabolism and redox homeostasis. It participates in oxidative reactions within the tricarboxylic acid cycle and electron transport chain, sustaining ATP synthesis and mitochondrial efficiency. Exercise influences multiple pathways of NAD metabolism, altering the NAD⁺\u002FNADH ratio and thereby affecting energy production and fatigue resistance. Studies have shown that both aerobic exercise and NAD precursor supplementation (e.g., nicotinamide riboside \\[NR\\]) can elevate body NAD levels and enhance mitochondrial function, though findings remain inconsistent due to variations in dosage and participants' characteristics. This study aims to investigate how acute NR supplementation interacts with Zone 2 cycling training in adults. Specifically, it examines the temporal and dose-dependent effects of NR supplementation on metabolic flexibility and exercise performance. The results may clarify the potential synergistic benefits of combining NAD supplementation with low-intensity endurance training to improve aerobic adaptability.",[28],"2026-03-16",{"date":332,"type":37},"2026-03-18",{"date":334,"type":37},"2026-01-06",{"date":336,"type":22},"2027-07",{"name":338,"class":101},"ZHANG Jiaqi",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":16,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":349,"conditions":350,"keywords":351,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":358,"completionDateStruct":360,"leadSponsor":362,"locationsCount":364},"100629680","a-muscle-brain-interplay-study-in-neurological-disorders-100629680","NCT07477821","A Muscle-brain Interplay Study in Neurological Disorders","A Translational Approach to Characterize the Muscle-brain Interplay in Neurological Non-communicable Diseases. The M-Brain Project","M-Brain","Inclusion Criteria:\n\nfor Good aging group:\n\n* Subjects aged 60 years or older\n* Frailty Index below the pathological cut-off (\\>0.25)\n* Absence of general cognitive impairment (MMSE \\> 24 points)\n* Absence of a diagnosis of sarcopenia\n\nfor Bad aging group:\n\n* Patients aged over 60 years\n* Exclusive presence of one of the following diagnoses:\n\n  1. Definite, probable, or probable laboratory-supported Amyotrophic Lateral Sclerosis (ALS), either sporadic or familial, according to the revised El Escorial Criteria for ALS diagnosis.\n  2. Parkinson's disease (PD) according to the MDS Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., Mov Disord., 2015 Oct; 30(12): 1591-1601).\n  3. Alzheimer's disease (AD), possible or probable, according to international diagnostic guidelines.\n  4. Diagnosis of severe acquired brain injury according to the Italian Guidelines for the Care of Patients in Vegetative State and Minimally Conscious State 2011 (approved by the Unified Conference on May 5, 2011 - Ministry of Health, Italy), with the presence of Sarcopenia.\n  5. Presence of Mild Cognitive Impairment (MCI), subjective memory complaint, or deficit in a single cognitive domain, according to international criteria and in absence of established neurological diseases and sarcopenia.\n  6. Presence of Sarcopenia as defined by the EWGSOP2 Sarcopenia Consensus, in the absence of cognitive deficits and established neurological diseases.\n\nExclusion Criteria:\n\n* Inability to provide informed consent.\n* Presence of severe and\u002For acute comorbidities (e.g., uncontrolled diabetes, heart failure, or a diagnosis of oncological disease), as determined by the research team.\n* Evidence of other previous neurological or psychiatric disorders involving the cognitive domain.\n* Uncontrolled or complicated systemic diseases or history of traumatic brain injury.\n* For subjects with Alzheimer's disease (AD), Parkinson's disease (PD), and Amyotrophic Lateral Sclerosis (ALS), individuals with a history of epilepsy will also be excluded.",{"count":348,"type":22},150,"Despite the improvements in life expectancy, neurodegenerative diseases (NDGs) have become the most dreaded disorders of older people. Aged brains show characteristic changes that are linked to neurodegeneration raising the question of whether these hallmarks represent the harbingers of NDGs. Lifestyle factors including, in particular physical exercise, have given particular attention to factors associated to movement issue as ones of the major factors in modulating the risk of developing NDGs, emphasizing the interest in the muscle-brain axis. Indeed, one of the crucial systems severely affected in several neuromuscular diseases is the loss of effective connection between muscle and nerve, and the neuromuscular junction (NMJ) represents the critical region at the level of which the two entities communicate.\n\nEven if controversy exists on whether pathological events beginning at the NMJ precede or follow loss of motor units, some recent data highlight as NGDs (e.g. Amyotrophic Lateral Sclerosis, Alzheimer's Disease, and Parkinson's Disease) and Aging share some common pathologic features such as the loss of fast-twich fiber, a decreased number of synaptic vesicles and sarcopenia giving evidence supports the notion that NMJ dismantlement can occur independently from motor neuron degeneration and may represent an early pathogenic signature of muscle-nerve communication defects.\n\nThe M-Brain project is an observational, analytical case-control study that will apply a new approach to interpret data underling the NMJ dismantlement in NDGs patients by comparing their clinical and biological information with data obtained from people who have had a so called \"good aging\" and those who have had a \"bad aging\".\n\nThe study will collect data useful to identify potential predisposing or risk factors for the subsequent development of a NDGs or able to predict the phenotype traiectories of selected pathologies with differerent movement levels. The combination of a muscular and neurological phenotyping and a biological characterization combining biomarkers, miRNA and extracellular vesicle (EV) assessments will allow to better identify the determinants of muscle-brain cross-talk that can then be used as potential indicators for the definition of critical morphological and functional components involved in aging and some NGDs. The project then will aim to identify phenotyope trajectories of patients giving particular attention to the brain-muscle axis and movement issues in order to provide information useful for future clinical strategies able to minimaze risk\u002Fpredisponent Factors.",[241,28],[352,353,354,355],"muscle","brain","aging","Neuromuscolar","2026-03-12",{"date":315,"type":37},{"date":359,"type":37},"2025-07-24",{"date":361,"type":22},"2027-02-28",{"name":363,"class":101},"Istituti Clinici Scientifici Maugeri SpA",4,{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":369,"acronym":370,"eligibilityCriteria":371,"healthyVolunteers":16,"sex":17,"minAge":281,"maxAge":4,"enrollmentInfo":372,"targetDuration":4,"studyType":23,"phases":374,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":384,"locationsCount":386},"100628761","prospective-multicentre-study-for-the-application-of-telomere-measurement-technology-as-a-tool-for-lung-cancer-diagnosis-100628761","NCT07465848","Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis","PneumoTAV001","Inclusion Criteria:\n\nCase Group:\n\n* Person aged 45 years or older at the time of signing the consent form.\n* Person with a current anatomopathologically confirmed diagnosis of small-cell or non-small cell lung cancer.\n* Not having received any oncological treatment prior to sample collection (surgery, radiotherapy, or systemic treatment with chemotherapy or immunotherapy).\n\nControl Group:\n\nCohort A (High risk controls):\n\n* Person aged 45 years or older at the time of signing the consent form.\n* High risk of lung cancer, defined as having a smoking history of at least 20 pack-year and currently smoking or having quit within the past 15 years.\n* No diagnosis or suspicion of lung cancer. Asymptomatic individuals who have undergone a chest computed tomography (CT) scan for lung cancer screening within the 12 months prior to signing the informed consent and as part of routine clinical practice, with a LUNG-RADS score of 3 or lower, will be included.\n\nCohort B (Low-risk controls):\n\n* Person aged 45 years or older at the time of signing the consent form.\n* Without high risk of lung cancer according to the criteria defined in cohort A.\n* No diagnosis or suspicion of lung cancer.\n\nExclusion Criteria:\n\n* History of any malignant neoplasm, except for subjects with tumors in localized stages who have undergone radical treatment and have been disease-free for at least five years.\n* Patient diagnosed with lung cancer who has already started oncological treatment before sample collection.\n* Patient who has undergone a biopsy or any invasive procedure or minor surgery less than 48 hours ago.\n* Patient who has undergone major surgery less than 7 days ago.\n* Patient with severe chronic kidney disease, defined as a glomerular filtration rate below 15 ml\u002Fmin.\n* Patient with severe liver disease, defined as Child-Pugh C.\n* Active infection, or treated less than 4 weeks ago.\n* Vulnerable population, for example, minors, prisoners, pregnant women, adults physically or mentally incapable of giving consent.",{"count":373,"type":22},1200,[84],"This research is a clinical performance study of in vitro diagnostic device (IVD), a prospective, multicentre, open-label, case-control clinical investigation aimed at constructing a predictive model that allows results to be classified as positive or negative in relation to the probability of having lung cancer.",[377,28,378],"Lung Cancer (Diagnosis)","Patient","2026-03-09",{"date":356,"type":37},{"date":382,"type":37},"2025-10-08",{"date":176,"type":22},{"name":385,"class":101},"Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)",12,{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100624738","phase-1-a-phase-ia-single-ascending-dose-study-of-subcutaneous-eb070-injection-in-healthy-volunteers-100624738","NCT07413536","A Phase Ia Single Ascending-Dose Study of Subcutaneous EB070 Injection in Healthy Volunteers","A Phase Ia Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous EB070 Injection in Healthy Volunteers","Inclusion Criteria:\n\n* Age: 18 to 60 years old.\n* Sex: Healthy male and female participants.\n* Body weight: ≥50 kg for males and ≥45 kg for females; body mass index (BMI = weight \\[kg\\] \u002F height \\[m²\\]) between 18 and 26 kg\u002Fm².\n* Participants of reproductive potential (both male and female) must agree to use reliable contraception (hormonal, barrier method, or abstinence) during the study and for at least 3 months after study completion. Female participants of childbearing potential must have a negative pregnancy test (β-HCG) at screening and baseline and must not be breastfeeding.\n* Informed consent: Participants must have been adequately informed about the study, voluntarily sign the informed consent form, and be willing and able to comply with study procedures.\n\nExclusion Criteria:\n\n* Abnormal findings at screening in physical examination, vital signs, 12-lead ECG, or laboratory tests (including hematology, urinalysis, blood biochemistry, coagulation function, and thyroid function) deemed clinically significant by the investigator.\n* Positive serology for any of the following: hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, or HIV antigen\u002Fantibody.\n* History of any clinically significant disease affecting the respiratory, digestive, cardiovascular, hematologic\u002Flymphatic, nervous, psychiatric, genitourinary, endocrine, hepatic, renal, dermatologic, or metabolic systems, or any other condition that could interfere with study results.\n* Blood pressure at screening: systolic ≥140 mmHg or \\\u003C90 mmHg, or diastolic ≥90 mmHg or \\\u003C50 mmHg.\n* Planned major surgery during the study, or major surgery within 1 month prior to randomization.\n* History of chronic infection, particularly bacterial, viral, fungal, or parasitic infection within 1 month prior to randomization.\n* Known allergy to EB070 or any excipients, history of hypersensitivity to antibody-based biologics, or history of specific allergic conditions (e.g., allergic conjunctivitis, allergic asthma, atopic dermatitis), or any clinically significant food, drug, insect bite, foreign protein, or monoclonal antibody allergy as judged by the investigator.\n* Alcohol abuse: ≥28 standard drinks per week within 1 year prior to randomization, or frequent drinking (\\>14 standard drinks\u002Fweek) within 6 months prior to randomization; or failed breath alcohol test (\\>0 mg\u002F100 mL) at screening or Day 1. (One standard drink contains 14 g alcohol, e.g., 360 mL beer, 45 mL 40% liquor, or 150 mL wine.)\n* Smoking ≥5 cigarettes per day or equivalent tobacco use (e.g., nicotine gum\u002Flozenges) within 3 months prior to randomization, inability to abstain during the study, or positive urine cotinine test at screening or Day 1.\n* Participation in any clinical trial of an investigational drug within 3 months prior to randomization (or within 5 half-lives, whichever is longer).\n* Use of any medications or dietary supplements (prescription, over-the-counter, herbal, or traditional Chinese medicine) within 14 days prior to randomization, or within 5 half-lives of the study drug.\n* Use of any biologic products within 3 months prior to randomization (or within 5 half-lives, whichever is longer).\n* Administration of live or attenuated vaccines within 1 month prior to randomization or planned during the study.\n* History of substance abuse (e.g., morphine, cannabis, methamphetamine, MDMA, ketamine) within 1 year prior to randomization, or positive urine drug screen at screening or Day 1.\n* Blood donation or significant blood loss (≥400 mL) within 3 months prior to randomization, or planned donation during the study or within 3 months after study completion.\n* History of syncope or needle phobia, or inability to tolerate blood draws.\n* Positive interferon-gamma release assay (T-SPOT.TB). Subjects without tuberculosis history or symptoms may be included if results are within twice the upper limit of normal.\n* Any other condition that the investigator judges makes the participant unsuitable for the study.",{"count":395,"type":22},36,[25],"The goal of this Phase Ia clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of EB070 injection following single ascending subcutaneous doses in healthy adult volunteers.\n\nThe main questions it aims to answer are:\n\nIs EB070 injection safe and well tolerated at increasing single subcutaneous dose levels in healthy subjects?\n\nWhat are the pharmacokinetic characteristics of EB070 after single-dose administration?\n\nThis is a single-center, randomized, double-blind, placebo-controlled, single ascending-dose (SAD) study. A total of 36 healthy volunteers will be enrolled and assigned to one of five dose cohorts (21 mg, 75 mg, 225 mg, 450 mg, or 600 mg). Subjects in each cohort will be randomized in a 3:1 ratio to receive a single subcutaneous injection of EB070 or placebo.\n\nA sentinel dosing strategy will be applied. In the 21 mg cohort, one subject will initially receive EB070. In the remaining cohorts, two sentinel subjects (one receiving EB070 and one receiving placebo) will be dosed first. Dose escalation and enrollment of the remaining subjects will proceed after evaluation of safety and tolerability within 48 hours after dosing.\n\nParticipants will:\n\nUndergo screening assessments prior to dosing\n\nReceive a single subcutaneous injection of EB070 or placebo\n\nStay in the Phase I unit for approximately 3 days for safety monitoring and pharmacokinetic and anti-drug antibody (ADA) sample collection\n\nReturn for scheduled outpatient visits for PK, ADA, and safety assessments through Day 113\n\nSafety will be assessed throughout the study by monitoring adverse events, vital signs, physical examinations, 12-lead ECGs, and laboratory tests. Pharmacokinetic parameters and anti-drug antibodies (ADA) will be evaluated as secondary outcomes.",[28],"2026-02-09",{"date":401,"type":37},"2026-02-17",{"date":403,"type":22},"2026-03",{"date":405,"type":22},"2027-03",{"name":407,"class":101},"Biotech Pharmaceutical Co., Ltd.",{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":16,"sex":17,"minAge":109,"maxAge":416,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":422,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":45},"100617750","dihydroberberine-effects-on-body-composition-and-metabolic-health-in-healthy-adults-100617750","NCT07322679","Dihydroberberine Effects on Body Composition and Metabolic Health in Healthy Adults","Effects of Dihydroberberine Supplementation on Body Composition, Glycemic Control, Energy Levels, Appetite, and Mood in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial","DHB","Inclusion Criteria:\n\n* 35 - 55 years of age (inclusive) at visit 1.\n* BMI ≥ 27.0 - ≤ 33.0 kg\u002Fm2.\n* Participant has a score of 7 - 10 on the Vein Access Scale Assessment at visit 1.\n* Non-user or former user (daily use; cessation ≥12 months) of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit 1, and has no plans to begin use during the study period.\n* Non-habitual users (i.e., daily or almost daily) of marijuana or hemp products, including CBD\u002FTHC products, and willing to abstain from use throughout the study period (topical creams\u002Flotions are allowed).\n* Willing to use personal smart phone with operating system capable of downloading and operating study applications (e.g., FitBit, smart scale, activity watch, etc).\n* Willing to adhere to all study procedures, including lifestyle considerations (see section 6.3), and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.\n\nExclusion Criteria:\n\n* Extreme dietary habits (e.g., ketogenic, very high protein, very high fiber, vegan\u002Fvegetarian) at the discretion of the Clinical Investigator.\n* Individuals undergoing moderate-to-intense activity (e.g., sports\u002Fexercise ≥ 5h\u002Fwk).\n* Recent weight changes (\\>4.5 kg ≤ 90 d of visit 1), or current\u002Fplanned engagement in a weight change program (e.g., weight loss or muscle gain) outside of the researcher-instructed, self-directed Lifestyle Intervention throughout the study period.\n* Abnormal laboratory test results of clinical significance at visit 1, at the discretion of the Clinical Investigator. One re-test will be allowed on a separate day prior to visit 2, for subjects with abnormal laboratory test results.\n* Uncontrolled and\u002For clinically important pulmonary (including uncontrolled asthma), cardiac (including, but not limited to, atherosclerotic disease, history of myocardial infarction, peripheral arterial disease, stroke), hepatic, renal, endocrine (including Type 1 and Type 2 diabetes mellitus), hematologic, immunologic, neurologic (such as Alzheimer's or Parkinson's disease), psychiatric (including depression and\u002For anxiety disorders) or biliary disorders. Conditions that are well-controlled or resolved will be assessed by the Clinical Investigator on a case-by-case basis.\n* Clinically important GI condition that would potentially interfere with the evaluation of the study product (e.g., inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, celiac disease, history of surgery for weight loss, gastroparesis, and clinically significant lactose or gluten intolerance or other food or ingredient allergies).\n* Uncontrolled hypertension (systolic blood pressure ≥ 140 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg. Stable use (no initiation or change in dose ≤ 90 d of visit 1) of FDA-approved medications for hypertension is allowed.\n* History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.\n* Signs or symptoms of an active infection of clinical relevance ≤ 5 d of visit 1. The visit may be rescheduled once all signs and symptoms have resolved (at the discretion of the Clinical Investigator) at least 5 d prior to visit 1.\n* Recent use (≤ 6 mo of visit 1) of any prescription anti-hyperglycemic\u002Fweight loss medication. This includes, but is not limited to: metformin, insulin, DPP-4 inhibitors, SGLT-2 inhibitors, GLP-1 agonist, GIP agonists, Pioglitazone and Sulfonylureas.\n* Use of any dietary supplement, other than conventional once-daily multivitamin\u002Fmineral supplements (within limits of the DRI) ≤ 14 d of visit 1 and throughout the study.\n* Recent history (≤ 12 months visit 1) of alcohol or substance abuse. Alcohol abuse is defined as \\>14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1½ oz distilled spirits).\n* Unstable use (change in dose) of any other prescription medications ≤ 90 d of visit 1, except for medications used PRN (e.g., asthma inhalers, non-drowsy seasonal allergy medications, etc.)\n* Antibiotic use ≤ 90 d of visit 1 and throughout the study period.\n* Regular use (≥ 3 days\u002Fweek ≤ 30 d of visit 1) of anti-inflammatory medications (e.g., NSAIDs) and throughout the study period.\n* Recent use of oral or injectable steroids, or topical or inhaled steroids (≥ 1500 µg\u002Fd) within 30 d of visit 1 and throughout the study period.\n* Exposure to any non-registered drug product ≤ 30 d prior to visit 1.\n* Diagnosed with major affective disorder, or other psychiatric disorder, that required hospitalization ≤ 12 months prior to visit 1.\n* Recent (≤ 90 d of visit 1) endoscopy and\u002For colonoscopy procedure.\n* Major trauma or any other surgical event ≤ 30 d of visit 1.\n* Currently scheduled, or planning to schedule, an elective surgical procedure during the study.\n* Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and is unwilling to commit to the use of a medically approved form of contraception throughout the study period. Women who become pregnant during the study will be discontinued.\n\nGeneral safety related criteria\n\n* Known sensitivity, intolerability, or allergy to any of the study products or study foods.\n* Has a condition the Clinical Investigator believes would interfere with his ability to provide informed consent, and comply with the study protocol, which might confound the interpretation of the study results, or put the participant at undue risk.","55 Years",{"count":418,"type":22},120,[84],"The goal of this clinical trial is to evaluate whether dihydroberberine (DHB) supplementation can improve body composition, blood sugar control, energy levels, appetite, and mood in healthy adults with overweight or mild obesity. The study focuses on men and women aged 35-55 years with a BMI between 27.0 and 33.0 kg\u002Fm².\n\nThe main questions it aims to answer are:\n\nDoes daily DHB supplementation lead to greater reductions in body weight over 12 weeks compared to placebo? Does DHB improve glycemic responses, appetite regulation, energy levels, and mood, both acutely (short-term) and chronically (over 12 weeks)?\n\nResearchers will compare two groups-one receiving DHB (400 mg\u002Fday) and the other receiving a placebo-administered as two capsules twice daily for 12 weeks. Participants will:\n\nAttend three in-clinic visits over approximately 14 weeks (including screening, baseline, and week 12 visits) Undergo mixed-meal tolerance tests (MTTs) to assess glucose metabolism, appetite, and energy levels Complete body composition assessments (including DXA scans), blood tests (e.g., glucose, insulin, HbA1c), and mood questionnaires (POMS-2) Be monitored for safety throughout the study",[28],[423,414,424,425,426,427,428,429,430,431,432,433,434,435],"Glucovantage®","Dihydroberberine","Body Composition","Glycemic Control","Energy Levels","Appetite","Mood","metabolism","Blood glucose","Body weight management","Waist circumference","Hip circumference","Leptin","2025-12-29",{"date":438,"type":37},"2026-01-07",{"date":440,"type":22},"2025-12-15",{"date":442,"type":22},"2026-09-25",{"name":444,"class":101},"Nanjing Nutrabuilding Bio-tech Co., Ltd.",{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":452,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":453,"conditions":454,"keywords":457,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":466,"leadSponsor":468,"locationsCount":45},"100612430","correlation-of-diaphragm-shear-wave-elastography-with-transdiaphragmatic-pressure-in-healthy-adults-a-feasibility-study-100612430","NCT07253480","Correlation of Diaphragm Shear-Wave Elastography With Transdiaphragmatic Pressure in Healthy Adults: a Feasibility Study","PLEASSURE 1","Inclusion Criteria:\n\n* 18-60 years, BMI 18-30 kg\u002Fm²\n* No known respiratory, neuromuscular, or cardiothoracic disease\n* Able to perform inspiratory maneuvers and consent.\n\nExclusion Criteria:\n\n* Pregnancy\n* History of smoking (\\> 10 pack years)\n* Impaired swallowing, as well as esophageal diseases, or disorders at the level of the gastroesophageal sphincter",{"count":386,"type":22},"Changes in intrapleural pressure after lung volume reduction in Chronic Obstructive Pulmonary disease (COPD) patients can lead to complications, including an increased risk of pneumothorax. This procedure, intended to improve lung function, may disturb the pressure balance within the pleural space, potentially precipitating pneumothorax. Careful monitoring of intrapleural pressure could help predict patients at risk. However, intrapleural pressure can currently only be measured invasively. Diaphragm shear-wave elastography (SWE) has been shown to reflect transdiaphragmatic pressure during isovolumetric inspiratory efforts and ventilation against inspiratory loading, and therefore may serve as a non-invasive surrogate for intrapleural pressure. This project outlines a stepwise study plan to evaluate SWE as a tool for intrapleural pressure monitoring (Figure 1). The project only moves to the next phase is the study previous phase was achieved successfully. The current protocol involves the first phase: to validate diaphragm SWE against transdiaphragmatic pressure and assess measurement reliability for local ultrasound systems in healthy adults.This prospective, single-centre, observational validation study will include twelve healthy adult volunteers. During a single study session, participants will perform standardized inspiratory efforts while simultaneous measurements of diaphragm SWE, transdiaphragmatic pressure (via esophageal and gastric balloon catheters), and mouth pressures are obtained. These methods are routinely applied in physiological research and carry minimal risk. Apart from brief nasal or throat discomfort during catheter placement, no significant adverse effects are expected. By establishing the relationship between diaphragm SWE, transdiaphragmatic pressure, and mouth pressures, this study aims to provide the essential validation step for future clinical research in COPD patients following lung volume reduction.",[455,456,28],"Diaphragm Ultrasound","Diaphragm Dysfunction",[458,459,460,461],"diaphragm","ultrasound","diaphragmatic pressure","shear-wave elastography","2025-11-29",{"date":464,"type":37},"2025-12-05",{"date":199,"type":22},{"date":467,"type":22},"2026-09",{"name":469,"class":101},"Isala",{"id":471,"slug":472,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":478,"targetDuration":4,"studyType":140,"phases":4,"briefSummary":480,"conditions":481,"keywords":489,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":501,"locationsCount":4},"100613748","french-military-firefighters-to-assess-relationships-between-exposome-and-health-100613748","NCT07270627","French Military Firefighters to Assess Relationships Between Exposome and Health.","Cohorte Militaire et Son Exposome : étude Pilote rétrospective au Sein de la Population Des Sapeurs-pompiers (Actuellement en Exercice et Anciens Sapeurs-pompiers) de la Brigade Des Sapeurs Pompiers de Paris","COMITEX-BSPP","Inclusion Criteria:\n\n* Active-duty or veteran military personnel from French Paris firefighter brigade.\n* Aged at least 18.\n* Not opposed to participate to the study\n\nExclusion Criteria:\n\n* Opposition to participate\n* veterans under legal protection",{"count":479,"type":22},15000,"The aim of the study is to describe professional exposures and health events among French military firefighters (both active-duty personnel and veterans) and identify potential relationships between the exposome (the total history of occupational and personal exposures) and health status in these populations. The study is based on a self-administered questionnaire that collects retrospective and present information about exposures and health conditions.",[28,482,483,484,485,486,487,488],"Exposure Occupational","Health Behavior, Risky","Occupational Health","Exposure","Firefighters","Military Personnel","Observational Study",[490,491,492,493,494],"Occupational exposure","health","military","exposome","occupational","2025-11-26",{"date":497,"type":37},"2025-12-08",{"date":499,"type":22},"2026-01-01",{"date":70,"type":22},{"name":502,"class":101},"Direction Centrale du Service de Santé des Armées",{"id":504,"slug":505,"hasResults":11,"nctId":506,"briefTitle":507,"officialTitle":508,"acronym":4,"eligibilityCriteria":509,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":510,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":512,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":149,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":4},"100609373","a-trial-to-investigate-the-new-caulis-pro-low-air-loss-lal-system-100609373","NCT07213739","A Trial to Investigate the New Caulis Pro® Low Air Loss (LAL) System","A Laboratory Trial to Investigate the Biomechanical and Physiological Responses to Prolonged Lying Postures During CLP When Combined With Pulsation Therapy on Caylis Pro® Low Air Loss (LAL) System","Inclusion Criteria:\n\n* Age 18-85\n* Healthy male or female\n\nExclusion Criteria:\n\n* Systemic skin disease\n* History of pressure ulcers in the sacrum or heels\n* Diabetes\n* Long term steroid use\n* Inability to maintain lying posture for prolonged periods","85 Years",{"count":166,"type":22},[84],"Investigation of biomechanical and physiological functions of laying on a new mattress in healthy volunteers.",[28,515],"Pressure Injury Prevention",[517],"caylis, Arjo","2025-10-02",{"date":520,"type":37},"2025-10-09",{"date":522,"type":22},"2025-09-30",{"date":150,"type":22},{"name":525,"class":44},"Arjo AB",{"id":527,"slug":528,"hasResults":11,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":281,"enrollmentInfo":533,"targetDuration":4,"studyType":23,"phases":535,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":45},"100608262","phase-1-a-study-to-evaluate-the-safety-immunogenicity-and-pharmacokinetics-of-gr2303-in-healthy-adult-100608262","NCT07199270","A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult","A Randomized, Double-blind, Placebo-controlled of GR2303 Injection in Healthy Adult Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Pharmacologic of GR2303","Inclusion Criteria:\n\n1. Healthy adult subjects\n2. Signed informed consent\n\nExclusion Criteria:\n\n1. History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.\n2. Prior use of drug targeting TNF-like cytokine 1A\n3. history of malignant tumor\n4. psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)",{"count":534,"type":22},64,[25],"he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups",[28],[539,540,541],"Inflamatory bowel disease","phase 1","GR2303","2025-09-22",{"date":522,"type":37},{"date":545,"type":37},"2025-09-18",{"date":547,"type":22},"2026-12-16",{"name":549,"class":44},"Genrix (Shanghai) Biopharmaceutical Co., Ltd."]